Published: 2020-12-11 16:45
Last Updated: 2021-03-06 16:28
An American government advisory panel endorsed widespread use of Pfizer’s COVID-19 vaccine Thursday, bringing the US closer to launching a vaccination campaign against coronavirus.
Depending on the Food and Drug Administration approval, vaccination could start in a few day. The president of the American Academy of Pediatrics Sally Goza said, “This is a light at the end of the long tunnel of this pandemic.”
The Pfizer vaccine and the German partner BioNTech were declared safe and effective for emergency use in people aged 16 and above, after 17 out of 22 advisors voted for it, four against it and only one abstained.
The news came after concerns were raised regarding allergic reactions following the roll-out of the Pfizer vaccine in the UK.
Coronavirus cases reached an all-time high in America with 3,100 deaths recorded Wednesday.
Pfizer announced that it will supply the US with 25 million doses of the two-shot vaccine by the end of the year. Priority will be given to health care workers, nursing home residents, and other vulnerable groups.
The FDA will review the Moderna and the National Institutes of Health vaccine next week. The third possible vaccine is byb Johnson & Johnson, followed by the vaccine from AstraZeneca and Oxford University.
The FDA issued a review of the vaccine this week with approximately 44,000 people showing strong protection, including people from various age groups, races and health conditions. No significant unexpected safety issues were detected.